Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondyloarthritis) and gastrointestinal or liver comorbidity

Pain Medication and Corticosteroid Use in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis in the United States: A Retrospective Observational Study

“…Glucocorticoids, NSAIDs, and opioids were the most-used pain medications across all indications in our study. Our findings are in corroboration with previous reports suggesting the use of NSAIDs and steroids in the management of pain in patients with AS, PsA, and RA [ 1 , 27 ]. Studies have also shown that long-term prescription of opioids in diseases such as RA and other chronic inflammatory arthritides is common [ 28 , 29 ].…”

“…2 Changes in pain medication use # 12 months before and after # biologic initiation in patients with A AS 1 , B PsA 2 , and C RA 3 . 1 For the AS cohort, N = 188; 2 For PsA cohort, N = 921; 3 For the RA cohort, N = 1599; * P \ 0.05 was considered statistically significant versus 12 months post-initiation of biologics. # Proportion of patients with C 1 fills.…”

Pain Medication and Corticosteroid Use in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis in the United States: A Retrospective Observational Study

“…Glucocorticoids, NSAIDs, and opioids were the most-used pain medications across all indications in our study. Our findings are in corroboration with previous reports suggesting the use of NSAIDs and steroids in the management of pain in patients with AS, PsA, and RA [ 1 , 27 ]. Studies have also shown that long-term prescription of opioids in diseases such as RA and other chronic inflammatory arthritides is common [ 28 , 29 ].…”

“…2 Changes in pain medication use # 12 months before and after # biologic initiation in patients with A AS 1 , B PsA 2 , and C RA 3 . 1 For the AS cohort, N = 188; 2 For PsA cohort, N = 921; 3 For the RA cohort, N = 1599; * P \ 0.05 was considered statistically significant versus 12 months post-initiation of biologics. # Proportion of patients with C 1 fills.…”

Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative

“…Data regarding the safety and efficacy of analgesic drugs in patients with IA and existing or prior gastrointestinal (GI) or hepatic morbidity could be identified for NSAIDs only [51]. In RA patients treated with NSAIDs there is an increased risk of GI events in individuals with prior uncomplicated GI events or a history of upper GI symptoms [52].…”

“…There is little evidence regarding the efficacy and safety of analgesic drugs in patients with IA and co-morbid hepatic disease [51] The experts believed that as the risk associated with the use of analgesics such as paracetamol, NSAIDs and opioids in patients with IA and liver disease is likely to be similar to that seen in other patients with hepatic dysfunction, prescribers should exercise a similar level of caution when using these drugs in IA patients as in other populations.…”

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib

“…In clinical practice, non-steroidal anti-inflammatory medicines (NSAIDs) are frequently replaced with filgotinib, a biologic disease-modifying antirheumatic medication [ 24 , 25 ]. Drug-drug interactions are less likely when filgotinib is metabolized by carboxylesterase isoform 2, which produces metabolites that have no reliance on the hepatic enzyme CYP450 [ 26 ].…”

Pain Medication and Corticosteroid Use in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis in the United States: A Retrospective Observational Study

“…Glucocorticoids, NSAIDs, and opioids were the most-used pain medications across all indications in our study. Our findings are in corroboration with previous reports suggesting the use of NSAIDs and steroids in the management of pain in patients with AS, PsA, and RA [ 1 , 27 ]. Studies have also shown that long-term prescription of opioids in diseases such as RA and other chronic inflammatory arthritides is common [ 28 , 29 ].…”

“…2 Changes in pain medication use # 12 months before and after # biologic initiation in patients with A AS 1 , B PsA 2 , and C RA 3 . 1 For the AS cohort, N = 188; 2 For PsA cohort, N = 921; 3 For the RA cohort, N = 1599; * P \ 0.05 was considered statistically significant versus 12 months post-initiation of biologics. # Proportion of patients with C 1 fills.…”

Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative

“…Data regarding the safety and efficacy of analgesic drugs in patients with IA and existing or prior gastrointestinal (GI) or hepatic morbidity could be identified for NSAIDs only [51]. In RA patients treated with NSAIDs there is an increased risk of GI events in individuals with prior uncomplicated GI events or a history of upper GI symptoms [52].…”

“…There is little evidence regarding the efficacy and safety of analgesic drugs in patients with IA and co-morbid hepatic disease [51] The experts believed that as the risk associated with the use of analgesics such as paracetamol, NSAIDs and opioids in patients with IA and liver disease is likely to be similar to that seen in other patients with hepatic dysfunction, prescribers should exercise a similar level of caution when using these drugs in IA patients as in other populations.…”

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib

“…In clinical practice, non-steroidal anti-inflammatory medicines (NSAIDs) are frequently replaced with filgotinib, a biologic disease-modifying antirheumatic medication [ 24 , 25 ]. Drug-drug interactions are less likely when filgotinib is metabolized by carboxylesterase isoform 2, which produces metabolites that have no reliance on the hepatic enzyme CYP450 [ 26 ].…”

Pain Medication and Corticosteroid Use in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis in the United States: A Retrospective Observational Study

“…Glucocorticoids, NSAIDs, and opioids were the most-used pain medications across all indications in our study. Our findings are in corroboration with previous reports suggesting the use of NSAIDs and steroids in the management of pain in patients with AS, PsA, and RA [ 1 , 27 ]. Studies have also shown that long-term prescription of opioids in diseases such as RA and other chronic inflammatory arthritides is common [ 28 , 29 ].…”

“…2 Changes in pain medication use # 12 months before and after # biologic initiation in patients with A AS 1 , B PsA 2 , and C RA 3 . 1 For the AS cohort, N = 188; 2 For PsA cohort, N = 921; 3 For the RA cohort, N = 1599; * P \ 0.05 was considered statistically significant versus 12 months post-initiation of biologics. # Proportion of patients with C 1 fills.…”

Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative

“…Data regarding the safety and efficacy of analgesic drugs in patients with IA and existing or prior gastrointestinal (GI) or hepatic morbidity could be identified for NSAIDs only [51]. In RA patients treated with NSAIDs there is an increased risk of GI events in individuals with prior uncomplicated GI events or a history of upper GI symptoms [52].…”

“…There is little evidence regarding the efficacy and safety of analgesic drugs in patients with IA and co-morbid hepatic disease [51] The experts believed that as the risk associated with the use of analgesics such as paracetamol, NSAIDs and opioids in patients with IA and liver disease is likely to be similar to that seen in other patients with hepatic dysfunction, prescribers should exercise a similar level of caution when using these drugs in IA patients as in other populations.…”

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib

“…In clinical practice, non-steroidal anti-inflammatory medicines (NSAIDs) are frequently replaced with filgotinib, a biologic disease-modifying antirheumatic medication [ 24 , 25 ]. Drug-drug interactions are less likely when filgotinib is metabolized by carboxylesterase isoform 2, which produces metabolites that have no reliance on the hepatic enzyme CYP450 [ 26 ].…”